HER-2/neu在卵巢癌组织中的表达及其临床意义

目的:研究HER-2/neu在卵巢肿瘤组织及正常卵巢组织中的表达,探讨其与卵巢癌发病的关系及其与临床病理参数的关系及临床意义。方法:收集60例卵巢病理标本。卵巢癌30例,卵巢良性肿瘤及正常卵巢组织各15例,采用组织芯片技术及免疫组织化学法(SP)检测卵巢癌中HER-2/neu的表达情况。结果:HER-2/neu在卵巢癌组织中的表达率为93.3%,与正常卵巢组织(6.7%)及卵巢良性肿瘤组织(26.7%)比较,差异有统计学意义(P<0.05);HER-2/neu在手术-病理分期为Ⅲ、Ⅳ期的卵巢癌组织中阳性表达率显著高于Ⅰ、Ⅱ期(P<0.05);不同组织学类型及组织学分级中卵巢癌组织中HER-2/neu蛋白阳性表达率差异无统计学意义(P>0.05)。结论:HER-2/neu在卵巢癌组织中呈高表达,HER-2/neu的阳性表达与卵巢癌的手术-病理分期有关联,与组织学类型及分级无关。

Expression of HER -2/neu in ovarian cancer tissues and its clinical significance

Objective:To study the expressions of HER-2/neu in ovarian carcinoma tissues and normal ovarian tissues,explore its relationship with the occurrence of ovarian cancer and clinical pathological parameters and its clinical significance.Methods:60 ovarian pathological samples were collected,including 30 samples of ovarian cancer,15 samples of benign ovarian tumor and 15 samples of normal ovary;tissue chip technique and immunohistochemical SP method were used to detect the expression of HER-2/neu in ovarian cancer.Results:The expression rate of HER-2/neu in ovarian cancer tissues was 93.3 %,compared with normal ovarian tissues(6.7%) and benign ovarian tumor tissues(26.7 %),there was significant difference(P<0.05);the positive expression rate of HER-2/neu in ovarian cancer with surgical-pathological staging Ⅲ and Ⅳ was significantly higher than that in ovarian cancer with surgical-pathological staging Ⅰ and Ⅱ(P<0.05);there was no significant difference in positive expression rate of HER-2/neu among ovarian cancer of different histological types and histological grades(P>0.05).Conclusion:High expression and positive expression of HER-2/neu in ovarian cancer tissues are related to surgical-pathological staging of ovarian cancer,which are not related to histological types and histological grades.